Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 1
1995 1
1997 1
1998 2
1999 2
2000 2
2003 3
2006 4
2007 11
2008 9
2009 2
2010 2
2011 3
2013 2
2014 4
2015 1
2016 2
2018 4
2019 1
2020 1
2021 3
2022 5
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
Smirnova E, Muthiah MD, Narayan N, Siddiqui MS, Puri P, Luketic VA, Contos MJ, Idowu M, Chuang JC, Billin AN, Huss RS, Myers RP, Boyett S, Seneshaw M, Min HK, Mirshahi F, Sanyal AJ. Smirnova E, et al. Among authors: billin an. Hepatology. 2022 Dec;76(6):1811-1824. doi: 10.1002/hep.32568. Epub 2022 Jun 23. Hepatology. 2022. PMID: 35561146 Free PMC article.
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Damgaard LH, Buchholtz K, Kjær MS, Balendran C, Myers RP, Loomba R, Noureddin M. Alkhouri N, et al. Among authors: billin an. J Hepatol. 2022 Sep;77(3):607-618. doi: 10.1016/j.jhep.2022.04.003. Epub 2022 Apr 16. J Hepatol. 2022. PMID: 35439567 Free article. Clinical Trial.
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.
Rasmussen DGK, Anstee QM, Torstenson R, Golding B, Patterson SD, Brass C, Thakker P, Harrison S, Billin AN, Schuppan D, Dufour JF, Andersson A, Wigley I, Shumbayawonda E, Dennis A, Schoelch C, Ratziu V, Yunis C, Bossuyt P, Karsdal MA. Rasmussen DGK, et al. Among authors: billin an. J Hepatol. 2023 Apr;78(4):852-865. doi: 10.1016/j.jhep.2022.11.028. Epub 2022 Dec 14. J Hepatol. 2023. PMID: 36526000 Free article. Review.
Rhabdomyosarcoma: current challenges and their implications for developing therapies.
Hettmer S, Li Z, Billin AN, Barr FG, Cornelison DD, Ehrlich AR, Guttridge DC, Hayes-Jordan A, Helman LJ, Houghton PJ, Khan J, Langenau DM, Linardic CM, Pal R, Partridge TA, Pavlath GK, Rota R, Schäfer BW, Shipley J, Stillman B, Wexler LH, Wagers AJ, Keller C. Hettmer S, et al. Among authors: billin an. Cold Spring Harb Perspect Med. 2014 Nov 3;4(11):a025650. doi: 10.1101/cshperspect.a025650. Cold Spring Harb Perspect Med. 2014. PMID: 25368019 Free PMC article. Review.
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
Xu J, Wang Y, Khoshdeli M, Peach M, Chuang JC, Lin J, Tsai WW, Mahadevan S, Minto W, Diehl L, Gupta R, Trauner M, Patel K, Noureddin M, Kowdley KV, Gulamhusein A, Bowlus CL, Huss RS, Myers RP, Chung C, Billin AN. Xu J, et al. Among authors: billin an. Hepatology. 2023 Jan 1;77(1):20-32. doi: 10.1002/hep.32599. Epub 2022 Jul 17. Hepatology. 2023. PMID: 35686937 Free PMC article.
Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.
Meng A, Humeniuk R, Jürgensmeier JM, Hsueh CH, Matzkies F, Grant E, Truong H, Billin AN, Yu H, Feng J, Kwan E, Tarnowski T, Nelson CH. Meng A, et al. Among authors: billin an. Clin Pharmacol Ther. 2022 Feb;111(2):416-424. doi: 10.1002/cpt.2439. Epub 2021 Oct 27. Clin Pharmacol Ther. 2022. PMID: 34623640 Free PMC article.
65 results